...
首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >Development of Either Split Tolerance or Robust Tolerance along with Humoral Tolerance to Donor and Third-Party Alloantigens in Nonmyeloablative Mixed Chimeras.
【24h】

Development of Either Split Tolerance or Robust Tolerance along with Humoral Tolerance to Donor and Third-Party Alloantigens in Nonmyeloablative Mixed Chimeras.

机译:在非清髓性混合嵌合体中对供体和第三方同种异体抗原的分裂耐受或鲁棒耐受的发展。

获取原文
获取原文并翻译 | 示例
           

摘要

Hematopoietic chimerism is considered to generate robust allogeneic tolerance; however, tissue rejection by chimeras can occur. This "split tolerance" can result from immunity toward tissue-specific Ags not expressed by hematopoietic cells. Known to occur in chimeric recipients of skin grafts, it has not often been reported for other donor tissues. Because chimerism is viewed as a potential approach to induce islet transplantation tolerance, we generated mixed bone marrow chimerism in the tolerance-resistant NOD mouse and tested for split tolerance. An unusual multilevel split tolerance developed in NOD chimeras, but not chimeric B6 controls. NOD chimeras demonstrated persistent T cell chimerism but rejected other donor hematopoietic cells, including B cells. NOD chimeras also showed partial donor alloreactivity. Furthermore, NOD chimeras were split tolerant to donor skin transplants and even donor islet transplants, unlike control B6 chimeras. Surprisingly, islet rejection was not a result of autoimmunity, since NOD chimeras did not reject syngeneic islets. Split tolerance was linked to non-MHC genes of the NOD genetic background and was manifested recessively in F(1) studies. Also, NOD chimeras but not B6 chimeras could generate serum alloantibodies, although at greatly reduced levels compared with nonchimeric controls. Surprisingly, the alloantibody response was sufficiently cross-reactive that chimerism-induced humoral tolerance extended to third-party cells. These data identify split tolerance, generated by a tolerance-resistant genetic background, as an important new limitation to the chimerism approach. In contrast, the possibility of humoral tolerance to multiple donors is potentially beneficial.
机译:造血嵌合体被认为可以产生强大的同种异体耐受性。但是,嵌合体可能会导致组织排斥。这种“分裂耐受性”可以由对造血细胞未表达的组织特异性Ag的免疫力引起。已知发生在皮肤移植的嵌合受体中,其他供体组织的报道却很少。由于嵌合体被认为是诱导胰岛移植耐受性的一种潜在方法,因此我们在耐受性NOD小鼠中产生了混合的骨髓嵌合体,并测试了分裂耐受性。在NOD嵌合体中出现了异常的多级分裂耐受性,但在嵌合B6对照中却没有。 NOD嵌合体表现出持续性T细胞嵌合体,但排斥其他供体造血细胞,包括B细胞。 NOD嵌合体还显示部分供体同种异体反应。此外,与对照B6嵌合体不同,NOD嵌合体对供体皮肤移植甚至供体胰岛移植具有分裂耐受性。出人意料的是,胰岛排斥反应不是自身免疫的结果,因为NOD嵌合体不排斥同基因胰岛。分裂耐受性与NOD遗传背景的非MHC基因有关,并在F(1)研究中隐性地表现出来。同样,NOD嵌合体而非B6嵌合体可产生血清同种抗体,尽管与非嵌合对照相比水平大大降低。令人惊讶的是,同种异体抗体反应具有足够的交叉反应性,以致嵌合体诱导的体液耐受性扩展到第三方细胞。这些数据确定了由耐受性遗传背景产生的分裂耐受性,是嵌合法的重要新局限。相反,对多个供体的体液耐受的可能性是潜在有益的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号